(Reuters) – Pfizer Inc said on Thursday it planned to file for full U.S. approval of its experimental coronavirus vaccine by April next year, even as the vaccine awaits emergency use authorization by the U.S. Food and Drug Administration.
The remarks were made by Pfizer executive William Gruber at a meeting of independent U.S. FDA advisers that are weighing emergency authorization of the vaccine made by Pfizer and German partner BioNTech SE.
(Reporting by Manas Mishra in Bengaluru; editing by Diane Craft)
